Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to evaluate the safety of the combination therapy of Lutetium (177Lu) DGUL and pembrolizumab. It will also assess the antitumor efficacy and pharmacokinetics of the combination therapy compared to Lutetium (177Lu) DGUL monotherapy. Participants will: Monotherapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals Combination therapy: Receive Lutetium (177Lu) DGUL 4 times (plus 2 additional doses) at 6-week intervals along with pembrolizumab up to 18 times at 6-week intervals
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 19 lat lub starsi
- •Potwierdzone schorzenie: rak gruczołowy prostaty z przerzutami
- •Bardzo niski poziom testosteronu (castration-resistant)
- •Wcześniejsze leczenie innymi lekami (abiraterone lub enzalutamide) bez sukcesu
- •Zmiana rozmiaru raka widoczna w badaniach obrazowych (PSMA-dodatnia)
- •Ogólny stan zdrowia pacjenta dobry do umiarkowango (ECOG 0-1)
- •Przewidywana długość życia co najmniej 6 miesięcy
- •Wystarczająca funkcja nerek, wątroby i prawidłowa liczba krwinek
Simplified criteria — AI translation
Trial details
- Minimum age
- 19 Years
- Last updated (source)
- October 7, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Seoul National University Hospital
Seoul, South Korea
Trial contact
Cellbi on
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/6/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.